- Home
- Asia Pacific Neuroendocrine Tumors Market
Asia-Pacific Neuroendocrine Tumors Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-301 | No of pages: 210 | Format:
Asia-Pacific neuroendocrine tumors market is projected to register a CAGR of 11.5% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028
Market Segmentation:
Asia-Pacific Neuroendocrine Tumors Market, By Classification (Functional Net and Non-Functional Net), Site (Lung, Pancreas, Gastrointestinal Tract (GI), Grade (Grade 1 {Low-Grade Tumor}, Grade 2 {Intermediate-Grade Tumor}, Grade 3 {High-Grade Tumor}), Type (Diagnosis and Treatment), Route of Administration (Oral and Parenteral), Mode of Purchase (Prescription and Over the Counter (OTC)), End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (Japan, China, Australia, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the Asia-Pacific neuroendocrine tumors market are:
The favourable reimbursement policies
Technological advancements in diagnostic instruments for detection of neuroendocrine tumor
The increased demand of targeted treatment options
Market Players:
The major players in Asia-Pacific neuroendocrine tumors market.
Novartis AG
Bristol-Myers Squibb Company
Pfizer Inc.
GlaxoSmithKline plc
Thermo Fisher Scientific Inc.
Hutchison China MediTech Limited
F. Hoffmann-La Roche Ltd
Bionano Genomics
Teva Pharmaceutical Industries Ltd.
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Sun Pharmaceutical Industries Ltd.
Illumina, Inc.
LUPIN
Ipsen Pharma
Viatris Inc.
Callisto Pharmaceuticals
Eli Lilly and Company
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 1.1 OBJECTIVES OF THE STUDY 1.2 MARKET DEFINITION 1.3 OVERVIEW OF THE ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET 1.4 CURRENCY AND PRICING 1.5 LIMITATIONS 1.6 MARKETS COVERED 2 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: SEGMENTATION 2.1 MARKETS COVERED 2.2 GEOGRAPHICAL SCOPE 2.3 YEARS CONSIDERED FOR THE STUDY 2.4 DBMR TRIPOD DATA VALIDATION MODEL 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.6 MULTIVARIATE MODELLING 2.7 CLASSIFICATION LIFELINE CURVE 2.8 DBMR MARKET POSITION GRID 2.9 VENDOR SHARE ANALYSIS 2.10 MARKET END USER COVERAGE GRID 2.11 SECONDARY SOURCES 2.12 ASSUMPTIONS 3 EXECUTIVE SUMMARY 4 PREMIUM INSIGHTS 5 PIPELINE ANALYSIS 6 PRICING ANALYSIS 7 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: REGULATIONS 7.1 REGULATORY PROCEDURE IN THE U.S. 7.2 REGULATORY PROCEDURE IN CANADA 7.3 REGULATORY PROCEDURE IN EUROPE 7.4 REGULATORY PROCEDURE IN CHINA 7.5 REGULATORY PROCEDURE IN MIDDLE EAST AND AFRICA 8 COMPARITIVE ANALYSIS BETWEEN MONOCLONAL AND POLYCLONAL ANTIBODY 8.1 MONOCLONAL ANTIBODY 8.2 POLYCLONAL ANTIBODY 9 MARKET OVERVIEW 9.1 DRIVERS 9.1.1 INCREASED INCIDENCE OF NEUROENDOCRINE TUMOR CASES 9.1.2 TECHNOLOGICAL ADVANCEMENT FOR THE DETECTION OF NEUROENDOCRINE TUMORS 9.1.3 GROWTH IN THE NUMBER OF PRIVATE DIAGNOSTIC CENTERS AND TREATMENT PROVIDERS 9.1.4 PRESENCE OF TARGETED TREATMENT OPTIONS 9.1.5 FAVORABLE REIMBURSEMENT POLICIES 9.2 RESTRAINTS 9.2.1 HIGH CAPITAL INVESTMENTS & LOW BENEFIT-COST RATIO FOR BIOMARKERS AND ORPHAN DRUGS 9.2.2 LACK OF AWARENESS AMONG THE POPULATION 9.2.3 UNMET NEEDS AND ACCESS TO MEDICAL RESOURCES IN SEVERAL REGIONS 9.2.4 HIGH COST OF DIAGNOSIS 9.3 OPPORTUNITIES 9.3.1 INCREASED GOVERNMENT INITIATIVES 9.3.2 EMERGING THERAPIES & DEVELOPMENT IN TREATMENT 9.3.3 RISING COLLABORATIONS AMONG THE MARKET PLAYERS 9.4 CHALLENGES 9.4.1 SIDE EFFECTS ASSOCIATED WITH TREATMENTS 9.4.2 STRINGENT GOVERNMENT REGULATIONS FOR THE DEVELOPMENT OF NEUROENDOCRINE TUMOR DRUGS 10 IMPACT OF COVID 19 ON ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET 10.1 PRICE IMPACT 10.2 IMPACT OF DEMAND 10.3 IMPACT ON SUPPLY CHAIN: 10.4 STRATEGIC DECISIONS: 10.5 CONCLUSION: 11 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 11.1 OVERVIEW 11.2 NON-FUNCTIONAL NET 11.3 FUNTIONAL NET 12 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY SITE 12.1 OVERVIEW 12.2 GASTROINTESTINAL TRACT (GI) 12.3 LUNGS 12.4 PANCREAS 13 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE 13.1 OVERVIEW 13.2 GRADE 2 (INTERMEDIATE-GRADE TUMOR) 13.3 GRADE 3 (HIGH-GRADE TUMOR) 13.4 GRADE 1( LOW-GRADE TUMOR) 14 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY TYPE 14.1 OVERVIEW 14.2 DIAGNOSIS 14.2.1 BLOOD TEST 14.2.2 IMAGING TEST 14.2.2.1 CTSCAN 14.2.2.2 MRI 14.2.2.3 OTHERS 14.2.3 BIOPSY 14.2.4 URINE TEST 14.2.5 OTHERS 14.3 TREATMENT 14.3.1 SOMATOSTATIN ANALOGS 14.3.1.1 OCTREOTIDE 14.3.1.2 LANREOTIDE 14.3.2 TARGETED THERAPY 14.3.2.1 EVEROLIMUS 14.3.2.2 SUNITINIB 14.3.2.3 OTHERS 14.3.3 RADIATION THERAPY 14.3.3.1 EXTERNAL-BEAM RADIATION 14.3.3.2 INTERNAL-BEAM RADIATION 14.3.4 SURGERY 14.3.4.1 CHOLECYSTECTOMY 14.3.4.2 OTHERS 14.3.5 LIVER-DIRECTED TREATMENT 14.3.5.1 RADIO FREQUENCY ABLATION (RFA) 14.3.5.2 HEPATIC ARTERY EMBOLIZATION 14.3.5.3 RADIOEMBOLIZATION 14.3.6 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)/ LUTATHERA 15 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION 15.1 OVERVIEW 15.2 ORAL 15.2.1 TABLETS 15.2.2 PILLS 15.2.3 OTHERS 15.3 PARENTERAL 15.3.1 SUBCUTANEOUS 15.3.2 INTRAMUSCULAR 15.3.3 OTHERS 16 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY END USER 16.1 OVERVIEW 16.2 HOSPITALS 16.3 SPECIALITY CLINICS 16.4 RADIATION CENTERS 16.5 HOME HEALTHCARE 16.6 OTHERS 17 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL 17.1 OVERVIEW 17.2 DIRECT TENDER 17.3 HOSPITAL PHARMACY 17.4 RETAIL SALES 17.5 ONLINE PHARMACY 17.6 OTHERS 18 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GEOGRAPHY 18.1 ASIA PACIFIC 18.1.1 CHINA 18.1.2 JAPAN 18.1.3 INDIA 18.1.4 AUSTRALIA 18.1.5 MALAYSIA 18.1.6 INDONESIA 18.1.7 SOUTH KOREA 18.1.8 SINGAPORE 18.1.9 PHILIPPINESS 18.1.10 THAILAND 18.1.11 VIETNAM 18.1.12 REST OF ASIA-PACIFIC 19 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: COMPANY LANDSCAPE 19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 20 SWOT 21 COMPANY PROFILES 21.1 F. HOFFMANN-LA ROCHE LTD 21.1.1 COMPANY SNAPSHOT 21.1.2 REVENUE ANALYSIS 21.1.3 COMPANY SHARE ANALYSIS 21.1.4 PRODUCT PORTFOLIO 21.1.5 RECENT DEVELOPMENTS 21.2 BRISTOL-MYERS SQUIBB COMPANY 21.2.1 COMPANY SNAPSHOT 21.2.2 REVENUE ANALYSIS 21.2.3 COMPANY SHARE ANALYSIS 21.2.4 PRODUCT PORTFOLIO 21.2.5 RECENT DEVELOPMENTS 21.3 VIATRIS INC. 21.3.1 COMPANY SNAPSHOT 21.3.2 COMPANY SHARE ANALYSIS 21.3.3 PRODUCT PORTFOLIO 21.3.4 RECENT DEVELOPMENTS 21.4 THERMO FISHER SCIENTIFIC INC. 21.4.1 COMPANY SNAPSHOT 21.4.2 REVENUE ANALYSIS 21.4.3 COMPANY SHARE ANALYSIS 21.4.4 PRODUCT PORTFOLIO 21.4.5 RECENT DEVELOPMENTS 21.5 NOVARTIS AG 21.5.1 COMPANY SNAPSHOT 21.5.2 REVENUE ANALYSIS 21.5.3 COMPANY SHARE ANALYSIS 21.5.4 PRODUCT PORTFOLIO 21.5.5 RECENT DEVELOPMENTS 21.6 REGENERON PHARMACEUTICALS, INC. 21.6.1 COMPANY SNAPSHOT 21.6.2 REVENUE ANALYSIS 21.6.3 PRODUCT PORTFOLIO 21.6.4 RECENT DEVELOPMENTS 21.7 ADVANCED ACCELERATOR APPLICATIONS (A SUBSIDIARY OF NOVARTIS AG) 21.7.1 COMPANY SNAPSHOT 21.7.2 REVENUE ANALYSIS 21.7.3 PRODUCT PORTFOLIO 21.7.4 RECENT DEVELOPMENTS 21.8 BIONANO GENOMICS 21.8.1 COMPANY SNAPSHOT 21.8.2 PRODUCT PORTFOLIO 21.8.3 RECENT DEVELOPMENTS 21.9 BIOSYNTHEMA INC. 21.9.1 COMPANY SNAPSHOT 21.9.2 PRODUCT PORTFOLIO 21.9.3 RECENT DEVELOPMENTS 21.10 CALLISTOPHARMA 21.10.1 COMPANY SNAPSHOT 21.10.2 PRODUCT PORTFOLIO 21.10.3 RECENT DEVELOPMENTS 21.11 ELI LILLY AND COMPANY 21.11.1 COMPANY SNAPSHOT 21.11.2 REVENUE ANALYSIS 21.11.3 PRODUCT PORTFOLIO 21.11.4 RECENT DEVELOPMENTS 21.12 EXACT SCIENCES CORPORATION 21.12.1 COMPANY SNAPSHOT 21.12.2 REVENUE ANALYSIS 21.12.3 PRODUCT PORTFOLIO 21.12.4 RECENT DEVELOPMENTS 21.13 GLAXOSMITHKLINE PLC 21.13.1 COMPANY SNAPSHOT 21.13.2 REVENUE ANALYSIS 21.13.3 PRODUCT PORTFOLIO 21.13.4 RECENT DEVELOPMENTS 21.14 HUTCHISON CHINA MEDITECH LIMITED 21.14.1 COMPANY SNAPSHOT 21.14.2 REVENUE ANALYSIS 21.14.3 PRODUCT PORTFOLIO 21.14.4 RECENT DEVELOPMENTS 21.15 IPSEN PHARMA 21.15.1 COMPANY SNAPSHOT 21.15.2 REVENUE ANALYSIS 21.15.3 PRODUCT PORTFOLIO 21.15.4 RECENT DEVELOPMENTS 21.16 ILLUMINA, INC. 21.16.1 COMPANY SNAPSHOT 21.16.2 REVENUE ANALYSIS 21.16.3 PRODUCT PORTFOLIO 21.16.4 RECENT DEVELOPMENTS 21.17 LUPIN 21.17.1 COMPANY SNAPSHOT 21.17.2 REVENUE ANALYSIS 21.17.3 PRODUCT PORTFOLIO 21.17.4 RECENT DEVELOPMENTS 21.18 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC. 21.18.1 COMPANY SNAPSHOT 21.18.2 REVENUE ANALYSIS 21.18.3 PRODUCT PORTFOLIO 21.18.4 RECENT DEVELOPMENTS 21.19 PFIZER INC. 21.19.1 COMPANY SNAPSHOT 21.19.2 REVENUE ANALYSIS 21.19.3 PRODUCT PORTFOLIO 21.19.4 RECENT DEVELOPMENTS 21.20 SUN PHARMACEUTICAL INDUSTRIES LTD. 21.20.1 COMPANY SNAPSHOT 21.20.2 REVENUE ANALYSIS 21.20.3 PRODUCT PORTFOLIO 21.20.4 RECENT DEVELOPMENTS 21.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. 21.21.1 COMPANY SNAPSHOT 21.21.2 REVENUE ANALYSIS 21.21.3 PRODUCT PORTFOLIO 21.21.4 RECENT DEVELOPMENTS 22 QUESTIONNAIRE 23 RELATED REPORTSSegmentation
Short Description Asia-Pacific Neuroendocrine Tumors Market, By Classification (Functional Net and Non-Functional Net), Site (Lung, Pancreas, Gastrointestinal Tract (GI), Grade (Grade 1 {Low-Grade Tumor}, Grade 2 {Intermediate-Grade Tumor}, Grade 3 {High-Grade Tumor}), Type (Diagnosis and Treatment), Route of Administration (Oral and Parenteral), Mode of Purchase (Prescription and Over the Counter (OTC)), End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (Japan, China, Australia, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2028 Market Definition: The intiation of tumor takes place when the DNA of healthy cells is damaged which causes the cells to change and grow in an uncontrolled manner, hence forming an aggregated mass of cells. A tumor can be cancerous and benign. A malignant cancerous tumor grows and spreads to other parts of the body if it is not found early and treated. A benign tumor can grow but will not spread. A benign tumor usually can be removed with use of minimally invasive surgery without it causing much harm. A neuroendocrine tumor (NET) begins in the specialized cells of the bodys neuroendocrine system. These cells have common traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the bodys organs and are responsible to control many of the bodys functions. All NETs are considered as malignant tumors. Most of the NETs take many years to develop and grow slowly. Market Segmentation: Neuroendocrine tumors market is segmented on the basis of classification, site, grade, type, route of administration, end user and distribution channel. On the basis of classification, the neuroendocrine tumors market is segmented into functional net and non-functional net On the basis of site, the neuroendocrine tumors market is segmented into lung, pancreas and gastrointestinal tract (GI) On the basis of grade, the neuroendocrine tumors market is segmented into grade 1 (low-grade tumor), grade 2 (intermediate-grade tumor) and grade 3 (high-grade tumor) On the basis of type, the neuroendocrine tumors market is segmented into diagnosis and treatment On the basis of route of administration, the neuroendocrine tumors market is segmented into oral and parenteral On the basis of end user, the neuroendocrine tumors market is segmented into hospitals, specialty clinics, radiation centers, home healthcare and others On the basis of distribution channel, the neuroendocrine tumors market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others Market Players The major players in Asia-Pacific neuroendocrine tumors market. Novartis AG Bristol-Myers Squibb Company Pfizer Inc. GlaxoSmithKline plc Thermo Fisher Scientific Inc. Hutchison China MediTech Limited F. Hoffmann-La Roche Ltd Bionano Genomics Teva Pharmaceutical Industries Ltd. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Sun Pharmaceutical Industries Ltd. Illumina, Inc. LUPIN Ipsen Pharma Viatris Inc. Callisto Pharmaceuticals Eli Lilly and CompanyMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.